Sort   by:  
 Page size 
UnknownOvCa-Chip microsystem recreates vascular endothelium-mediated platelet extravasation in ovarian cancer.
Not available
S-EPMC7391144 | biostudies-literature
TranscriptomicsOvarian Cancer Dataset
Background. Genome-wide expression changes are associated with development of chemoresistance in patients with ovarian cancer (OVCA); the BCL2 antagonist of cell death (BAD) apoptosis pathway may play a role in clinical outcome. Methods. We analyzed specimens and/or genomic data from 1,406 patients...
ORGANISM(S): Homo sapiens 
2011-10-02 | E-GEOD-23554 | biostudies-arrayexpress
ProteomicsPRAME and CTCFL-reactive TCRs for the treatment of ovarian cancer
Recurrent disease emerges in the majority of patients with ovarian cancer (OVCA). Adoptive T-cell therapies with T-cell receptors (TCRs) targeting tumor-associated antigens (TAAs) are considered promising solutions for less-immunogenic ‘cold’ ovarian tumors. In order to treat a broader patient popul...
ORGANISM(S): Homo sapiens (Human) 
2023-03-10 | PXD040651 | Pride
Ovarian cancer  prame  ctcfl  cldn6  tcr gene transfer  t-cell therapy  immunotherapy  peptide  allogeneic hla 
UnknownAssociation between targeted somatic mutation (TSM) signatures and HGS-OvCa progression.
Not available
S-EPMC5055158 | biostudies-literature
UnknownSafety and efficacy of dendritic cell-based immunotherapy DCVAC/OvCa added to first-line chemotherapy (carboplatin plus paclitaxel) for epithelial ovarian cancer: a phase 2, open-label, multicenter, randomized trial.
Not available
S-EPMC8739446 | biostudies-literature
TranscriptomicscaArray_cho-00156: Gene Expression in Ovarian Cancer Reflects Both Morphology and Biological Behavior
Biologically and clinically meaningful tumor classification schemes have long been sought. Some malignant epithelial neoplasms, such as those in the thyroid and endometrium, exhibit more than one pattern of differentiation, each associated with distinctive clinical features and treatments. In other ...
ORGANISM(S): Homo sapiens 
2015-05-07 | E-GEOD-68600 | biostudies-arrayexpress
TranscriptomicsGene expression changes with induction of in-vitro platinum-resistance in ovarian cancer cell lines.
We treated 8 human ovarian cancer cell lines with cisplatin in treatment/recovery cycles to induce in-vitro resistance to the drug. Microarrays measured gene expression at baseline and after each dose schedule (after recovery). OVCA cells lines (T8, OVCAR5, OV2008, IGROV1, C13, A2780S, A2780CP, and ...
ORGANISM(S): Homo sapiens 
2011-10-02 | E-GEOD-23553 | biostudies-arrayexpress
ProteomicsA Multi-Faceted Analysis Showing CRNDE Transcripts and a Recently Confirmed Micropeptide as Important Players in Ovarian Carcinogenesis (identification of the CRNDEP micropeptide by immunoprecipitation followed by MS in one OvCa sample)
Abstract: CRNDE is considered an oncogene expressed as long non-coding RNA. Our previous paper is the only one reporting CRNDE as a micropeptide-coding gene. The amino acid sequence of this micropeptide (CRNDEP) has recently been confirmed by other researchers. This study aimed at the mass spectrome...
ORGANISM(S): Homo sapiens (Human) 
2024-04-28 | PXD044196 | Pride
Dna sequence variant Protein expression Cytoskeleton Microtubule Ovarian cancer Micropeptide Mass spectrometry Nucleolus Lncrna Tp53 Sep Crnde Centrosome Affinity chromatography Microtubular toxin Adhesion Dna methylation Rna-seq 
GenomicsGene Expression Profiling of TNBC and OVCA in response to Azacitidine and Talazoparib (RNA-Seq)
Gene Expression Profiling of TNBC and OVCA in response to Azacitidine and Talazoparib (RNA-Seq)
PRJNA635430 | ENA
GenomicsGene expression profiling of TNBC and OVCA cell lines in response to Azacitidine and Talazoparib
Gene expression profiling of TNBC and OVCA cell lines in response to Azacitidine and Talazoparib
PRJNA631733 | ENA
Sort   by:  
 Page size